Key result
Hyperhomocysteinemia is linked to ~88% higher all-cause mortality in adults with diastolic dysfunction.
Why the study?
It is unknown whether serum homocysteine level predicts outcomes in patients with diastolic dysfunction.
Does hyperhomocysteinemia predict all-cause death in adults with diastolic dysfunction?
Cohort (n=231)
Does hyperhomocysteinemia predict all-cause death in adults with diastolic dysfunction?
Hazard Ratio: 1.88 (95% CI 1.07–3.29)
Elevated plasma homocysteine levels are significantly associated with an increased risk of all-cause mortality in community-dwelling adults with diastolic dysfunction.
May aid risk stratification in diastolic dysfunction; hypothesis-generating and should not yet change practice.
Hyperhomocysteinemia (HHCYS) has been associated with systolic heart failure. However, it is still unknown that serum homocycsteine level was useful in predicting the outcome in patients with diastolic dysfunction. We conducted a cohort study to determine if HHCYS was associated with poor prognosis in diastolic dysfunction patients. The Chin-Shan Community Cardiovascular Cohort (CCCC) study was designated to investigate the trends of cardiovascular morbidity and mortality in a community. Individuals who were 35 years and above were enrolled. Participants were categorized by homocysteine concentration quartiles. We used multivariate Cox proportional hazards models to calculate the hazard ratio (HR) of the 4th quartiles versus the 1st quartile. Area under the receiver-operating characteristic (ROC) curve was to compare prediction measures. A total of 2020 participants had completed the echocardiography examination, and 231 individuals were diagnosed as diastolic dysfunction. A total 75 participants had died during follow-up period. HHCYS was found to be significantly associated with poor prognosis. The adjusted HR for homocysteine level was 1.07 (95% confidence interval [CI], 1.01-1.14). Participants in the highest quartile had a 1.90 (95% CI, 0.88-4.12, P for trend, .026) fold risk for all cause death, compared with those in the lowest quartiles. The HR was 1.88 (95% CI, 1.07-3.29) using 11.11 μmol/L as cut point for hyperhomocysteine. HHCYS was significantly associated with poor prognosis in diastolic dysfunction participants in the community.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2017) conducted a cohort in Diastolic dysfunction (n=231). Hyperhomocysteinemia vs. Homocysteine < 11.11 μmol/L was evaluated on All-cause death (HR 1.88, 95% CI 1.07-3.29). Hyperhomocysteinemia (≥11.11 μmol/L) was significantly associated with an increased risk of all-cause death in adults with diastolic dysfunction (HR 1.88; 95% CI 1.07-3.29).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: